Dyne Therapeutics
NASDAQ: DYNWaltham, US · Founded 2017 · Delaware corporation · 316 employees on LinkedIn · 5 known investors
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.
Founders & leadership
Dyne Therapeutics was founded in 2017 by Romesh Subramanian, Ph.D..
RS
Romesh Subramanian, Ph.D.Founder
RS
Richard ScalzoExecutive
JB
Joshua BrummExecutive
JM
Jonathan McNeill, M.D.Executive
OB
Oxana Beskrovnaya, Ph.D.Executive
Board
LK
Lawrence Klein, Ph.D.Board director
DK
CS
Catherine Stehman-Breen, M.D.Board director
JR
DL
David LubnerBoard director
EH
Investors · 5
Reported raises · per SEC filings
Form D private placements$115.7M disclosed across 1 round · 2020
▶$115.7MraisedAug 2020 · 19 investors · BiotechnologyRule 506(b)
▶$115.7MraisedAug 2020 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence Klein, Ph.D.Director
- Richard ScalzoExecutive Officer
- Joshua BrummExecutive Officer, Director
- David LubnerDirector
- Edward HurwitzDirector
- Dirk KerstenDirector
- Jonathan McNeill, M.D.Executive Officer
- Catherine Stehman-Breen, M.D.Director
- Jason RhodesDirector
- Oxana Beskrovnaya, Ph.D.Executive Officer
- Romesh Subramanian, Ph.D.Executive Officer
- Offering amount
- $115.7M
- Amount sold
- $115.7M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Dyne Therapeutics went on to found or lead other companies.
Competitors · 4
by search overlap
Seeking Alpha34 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood32 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall St31 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Public28 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies competing with Dyne Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Dyne Therapeutics do?
- Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.
- Who founded Dyne Therapeutics?
- Dyne Therapeutics was founded by Romesh Subramanian, Ph.D. in 2017.
- Who are Dyne Therapeutics's investors?
- Dyne Therapeutics's investors include Atlas Venture, MPM BioImpact, Vida Ventures, Forbion, Hercules Capital, Inc..
- How much funding has Dyne Therapeutics raised?
- Dyne Therapeutics has disclosed $115.7M raised across 1 round.
- Where is Dyne Therapeutics headquartered?
- Dyne Therapeutics is headquartered in Waltham, US.